To demonstrate that zalcitabine (dideoxycytidine; ddC) monotherapy is safe and tolerable in
the treatment of patients with AIDS or advanced AIDS related complex (ARC) who previously
demonstrated intolerance to zidovudine (AZT) treatment while in Protocol N3300 (NIAID ACTG
114) or N3492 (NIAID ACTG 119).
Patients on amphotericin, pyrimethamine, sulfadiazine, trimethoprim/sulfamethoxazole,
ganciclovir, intravenous pentamidine, intravenous acyclovir or oral acyclovir or other bone
marrow or renal toxic drugs may not tolerate concomitant ddC. If these drugs are given
concomitantly with ddC, patients should have frequent clinical and laboratory assessments, as
appropriate. Drugs that are nephrotoxic or have the potential to cause peripheral neuropathy
might be expected to cause increased toxicity when co-administered with ddC. Drugs that could
cause serious additive toxicity when co-administered with study medication will be allowed
for treatment of an acute intercurrent illness or opportunistic infection at the discretion
of the investigator. Their use may be allowed with interruption of study drug for up to 35
days per episode, for a total of 90 days for the study. If the patient's condition requires
chronic administration of these medications, the patient will be discontinued from study
medication and followed.
Inclusion Criteria
Concurrent Medication:
Recommended:
- Prophylactic aerosolized pentamidine.
- Allowed for maintenance after recovering from infection for which initially
prescribed:
- Pyrimethamine.
- Sulfadiazine.
- Amphotericin.
- Fluconazole.
- Ketoconazole (= or < 400 mg/day).
- Acyclovir ( = or < 1000 mg/day).
- Ganciclovir.
- Medications for tuberculosis or Mycobacterium avium infection.
- Allowed:
- Erythropoietin.
- Megace.
- Trimethoprim/sulfamethoxazole < or = 20 mg/kg/day.
- Nystatin.
- Low dose acetaminophen or non-steroidal anti-inflammatory agents ( = or < 3 g/day).
- Medications on which patient has been stable for 14 days prior to study entry.
- Allowed if no evidence of peripheral neuropathy at study entry:
- Isoniazid (must be receiving pyridoxine = or > 50 mg/day concomitantly).
- Phenytoin, if stable for = or > 3 months.
- Metronidazole with a study medication interruption and pre and post testing for
peripheral neuropathy. Any signs of this and the patient will not be restarted on
study medication.
- REFER TO NOTE OF CAUTION IN PROTOCOL SUMMARY.
Patients must have the following:
- Previously enrolled in NIAID ACTG 114 or NIAID ACTG 119.
- Experienced = or > grade 3 zidovudine (AZT) related toxicity while enrolled in the
assigned protocol and followed the procedures for the study drug dose reduction,
interruption, rechallenge and permanent discontinuation as per NIAID ACTG 114 or NIAID
ACTG 119.
- NOTE:
- After permanent study drug discontinuation from NIAID ACTG 114 the drug code may be
broken ONLY after discussion with Hoffmann-La Roche regarding toxicity management and
probable relationship to AZT. Although NIAID ACTG 119 is an open-label study,
investigators should also contact Hoffmann-La Roche prior to entering any patient into
this protocol.
- Toxicities must be "probably" AZT related (as determined by the investigator and
following discussion by sponsor) for patients to be eligible for inclusion into this
protocol.
- Toxicities must be resolved to = or < grade 2 within 45 days of discontinuation from
AZT in NIAID ACTG 114 or NIAID ACTG 119.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
- An active AIDS defining opportunistic infection or other active intercurrent illnesses
if their ongoing treatment requires the use of excluded medications (see Exclusion -
Concurrent Medications).
- Baseline fever > 38. 5 C if caused by an occult opportunistic infection or neoplasm and
requiring continuous treatment with excluded medications. If the evaluation for
infection is unrevealing, the patient may be entered after the evaluation is completed
but while mycobacterial cultures are still pending. Patients with a history of
unexplained fever > 38. 5 C should be evaluated as above and/or be afebrile (T < 38. 0
C) for 2 weeks prior to study entry.
- Severe AIDS dementia complex as defined by a score of < 23 on the Mini-Mental State
Exam at the time of discontinuation from NIAID ACTG 114 or NIAID ACTG 119.
- Any history of peripheral neuropathy or moderate to severe peripheral neuropathy as
defined below:
- A score of = or > 4 in any one category or a score of = or > 2 in two categories of
the peripheral neuropathy segment of the Signs and Symptoms Questionnaire.
- Accompanied by:
- Results on the Standardized Neurological exam indicative of a moderate abnormality,
particularly impaired sensation of sharp pain, light touch or vibration in lower
extremities, distal extremity weakness or distal extremity hyporeflexia.
- Significant cardiac disease, defined as history of ventricular arrhythmias requiring
medication, prior myocardial infarct or history of angina or ischemia changes on EKG.
- Significant liver disease, as defined by transaminases > 5 x upper limit of normal or
a history of cirrhosis or ascites.
- Significant renal disease as defined by an estimated creatinine clearance < 50
ml/min.
Concurrent Medication:
Excluded:
- Other antiretroviral agents.
- Biologic modifiers.
- Corticosteroids.
- Other experimental agents including:
- Foscarnet.
- Ribavirin.
- ddI.
- Drugs that could cause peripheral neuropathy including:
- Hydralazine.
- Nitrofurantoin.
- Vincristine.
- Cisplatin.
- Dapsone.
- Disulfiram.
- Diethyldithiocarbamate.
Patients with the following are excluded:
- An active AIDS defining opportunistic infection or other active intercurrent illnesses
if their ongoing treatment requires the use of excluded medications (see Exclusion -
Concurrent Medications). Such patients will be allowed into the study if they have
completed therapy with an excluded concomitant medication and are stable for 14 days.
Had to discontinue study medication in NIAID ACTG 114 or NIAID ACTG 119 because of an
opportunistic infection or intercurrent illness which required continuous treatment
with medications allowed for concomitant administration in NIAID ACTG 114 or ACTG 119.
Symptoms and conditions defined in patient Exclusion - Co-Existing Condition. Active
substance or alcohol abuse. Unwillingness or deemed unable to sign informed consent.
Prior Treatment:
Excluded within 30 days of study entry:
- Radiation therapy.
Active substance or alcohol abuse.
Mount Zion Med Ctr, San Francisco, California 94115, United States
Davies Med Ctr, San Francisco, California 94114, United States
Dr Robert Swartz, Fort Myers, Florida 33901, United States
Med Service, Miami, Florida 33125, United States
Ctr for Special Immunology, Fort Lauderdale, Florida 33308, United States
AIDS Research Consortium of Atlanta, Atlanta, Georgia 30308, United States
Henry Ford Hosp, Detroit, Michigan 48202, United States
Graduate Hosp, Philadelphia, Pennsylvania 19146, United States
Humana Hosp / Med City Dallas, Dallas, Texas 75230, United States
